In the last trading session, 1.52 million Spyre Therapeutics Inc (NASDAQ:SYRE) shares changed hands as the company’s beta touched 2.75. With the company’s per share price at $11.80 changed hands at -$0.59 or -4.76% during last session, the market valuation stood at $711.03M. SYRE’s last price was a discount, traded about -246.02% off its 52-week high of $40.83. The share price had its 52-week low at $11.60, which suggests the last value was 1.69% up since then. When we look at Spyre Therapeutics Inc’s average trading volume, we note the 10-day average is 1.02 million shares, with the 3-month average coming to 672.33K.
Analysts gave the Spyre Therapeutics Inc (SYRE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.27. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SYRE as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Spyre Therapeutics Inc’s EPS for the current quarter is expected to be -0.84.
Spyre Therapeutics Inc (NASDAQ:SYRE) trade information
Instantly SYRE was in red as seen at the end of in last trading. With action -22.85%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -49.31%, with the 5-day performance at -22.85% in the red. However, in the 30-day time frame, Spyre Therapeutics Inc (NASDAQ:SYRE) is -36.73% down. Looking at the short shares, we see there were 10.77 million shares sold at short interest cover period of 16.54 days.
The consensus price target for the stock as assigned by Wall Street analysts is 50, meaning bulls need an upside of 76.4% from its current market value. According to analyst projections, SYRE’s forecast low is 40 with 71 as the target high. To hit the forecast high, the stock’s price needs a -501.69% plunge from its current level, while the stock would need to soar -238.98% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 44.65%. The 2025 estimates are for Spyre Therapeutics Inc earnings to decrease by -8.35%, but the outlook for the next 5-year period is at -5.20% per year.
SYRE Dividends
Spyre Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Spyre Therapeutics Inc (NASDAQ:SYRE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.72% of Spyre Therapeutics Inc shares while 101.11% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.77%. There are 101.11% institutions holding the Spyre Therapeutics Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 16.568% of the shares, roughly 7.51 million SYRE shares worth $176.51 million.
FAIRMOUNT FUNDS MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 8.8668% or 4.02 million shares worth $94.47 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund . With 1.66 shares estimated at $19.59 million under it, the former controlled 2.76% of total outstanding shares. On the other hand, Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund held about 2.30% of the shares, roughly 1.39 shares worth around $16.37 million.
